Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 11:15 a.m. PT in San Francisco.
波士頓，2025年1月8日（全球新聞社）-- Verve Therapeutics是一家臨牀階段公司，正在開發一種新的基因藥物用於心血管疾病，今天宣佈，聯創和首席執行官Sekar Kathiresan萬.D.將在2025年1月15日星期三上午11:15在舊金山舉行的第43屆摩根大通醫療會議上進行演講。
A live webcast will be available in the investor section of the company's website at . The webcast will be archived for 30 days following the presentation.
公司的投資者網站上將提供直播網絡廣播。演講後，網絡廣播將保存30天。
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic management to single-course gene editing medicines. The company's lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). For more information, please visit .
關於Verve Therapeutics
Verve Therapeutics, Inc.（納斯達克：VERV）是一家臨牀階段公司，正在開發一種新的基因藥物，用於心血管疾病，具有將治療從慢性管理轉變爲單次基因編輯藥物的潛力。公司的主要項目——VERVE-101、VERVE-102和VERVE-201——靶向已經廣泛驗證爲降低低密度脂蛋白膽固醇（LDL-C）的靶基因，後者是動脈粥樣硬化心血管疾病（ASCVD）的根本原因。VERVE-101和VERVE-102旨在永久關閉肝臟中的PCSK9基因，最初針對的是雜合子家族高膽固醇血癥（HeFH），並最終用於治療因高LDL-C水平而持續受影響的確診ASCVD患者。VERVE-201旨在永久關閉肝臟中的ANGPTL3基因，最初用於治療難治性高膽固醇血癥，即患者在接受最大耐受治療後仍高LDL-C，以及純合子家族高膽固醇血癥（HoFH）。欲了解更多信息，請訪問。
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
投資者聯繫
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
媒體聯繫
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
譯文內容由第三人軟體翻譯。
